Mavelertinib, also known as PF06747775, is a third-generation covalent inhibitor of EGFR, with low brain permeability and promising results in phase I clinical trials for the treatment of EGFR-driven NSCLC [195,197]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.